- Home
- PRTG vs BIVI Comparison
PRTG vs BIVI Comparison
Compare PRTG & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- BIVI
- Stock Information
- Founded
- PRTG 1973
- BIVI 2013
- Country
- PRTG British Virgin Islands
- BIVI United States
- Employees
- PRTG N/A
- BIVI N/A
- Industry
- PRTG Oil & Gas Production
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- BIVI Health Care
- Exchange
- PRTG Nasdaq
- BIVI Nasdaq
- Market Cap
- PRTG 17.7M
- BIVI 15.0M
- IPO Year
- PRTG N/A
- BIVI N/A
- Fundamental
- Price
- PRTG $5.91
- BIVI $8.70
- Analyst Decision
- PRTG
- BIVI
- Analyst Count
- PRTG 0
- BIVI 0
- Target Price
- PRTG N/A
- BIVI N/A
- AVG Volume (30 Days)
- PRTG 231.6K
- BIVI 50.8K
- Earning Date
- PRTG 08-26-2025
- BIVI 05-12-2025
- Dividend Yield
- PRTG N/A
- BIVI N/A
- EPS Growth
- PRTG N/A
- BIVI N/A
- EPS
- PRTG N/A
- BIVI N/A
- Revenue
- PRTG N/A
- BIVI N/A
- Revenue This Year
- PRTG N/A
- BIVI N/A
- Revenue Next Year
- PRTG N/A
- BIVI N/A
- P/E Ratio
- PRTG N/A
- BIVI N/A
- Revenue Growth
- PRTG N/A
- BIVI N/A
- 52 Week Low
- PRTG $2.10
- BIVI $6.20
- 52 Week High
- PRTG $23.01
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- PRTG 45.85
- BIVI 44.26
- Support Level
- PRTG $5.60
- BIVI $6.54
- Resistance Level
- PRTG $6.20
- BIVI $10.30
- Average True Range (ATR)
- PRTG 0.42
- BIVI 0.77
- MACD
- PRTG 0.10
- BIVI -0.06
- Stochastic Oscillator
- PRTG 65.45
- BIVI 45.55
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.